Septerna Financial Statements
NASDAQ: SEPNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Septerna revenue and earnings
In fiscal 2025, Septerna generated $46.0 million in revenue, up 4174.5% from fiscal 2024, its 2nd consecutive year of revenue growth. Septerna reported a net loss of $48.9 million, compared with a loss of $71.8 million a year earlier. Operating margin was -148.6%.
Diluted earnings per share came in at -$1.10. Over the last 2 fiscal years, SEPN's revenue has grown at a 1644.5% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Septerna income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Revenue | 45.95M | 1.07M | 151.00K |
| Revenue growth (YoY) | +4174.51% | +611.92% | — |
| Operating Expenses | 114.25M | 81.90M | -1.92M |
| Research & Development | 97.58M | 65.34M | 35.98M |
| Operating Income | -68.30M | -80.82M | 2.08M |
| Other Income (Expense) | 19.43M | 8.53M | 2.80M |
| Pretax Income | -48.87M | -72.30M | -48.87M |
| Income Tax | 12.00K | -498.00K | 691.00K |
| Net Income | -48.88M | -71.80M | 4.18M |
| Net Income growth (YoY) | — | -1817.66% | — |
| EPS (Basic) | -1.10 | -7.26 | 0.29 |
| EPS (Diluted) | -1.10 | -7.26 | 0.29 |
| Shares Outstanding (Basic) | 44.26M | 9.89M | 1.93M |
| Shares Outstanding (Diluted) | 44.26M | 9.89M | 2.18M |
| EBITDA | -66.70M | -79.42M | 2.88M |
| Operating Margin | -148.63% | -7518.42% | 1374.17% |
| Net Margin | -106.37% | -6678.88% | 2768.21% |
This table shows 3 annual periods of Septerna's income statement, from FY 2025 back to FY 2023, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow SEPN's reporting calendar. What is a income statement?